tiprankstipranks
Shanghai Kindly Medical Instruments Co., Ltd. Class H (HK:1501)
:1501
Hong Kong Market
Want to see HK:1501 full AI Analyst Report?

Shanghai Kindly Medical Instruments Co., Ltd. Class H (1501) AI Stock Analysis

2 Followers

Top Page

HK:1501

Shanghai Kindly Medical Instruments Co., Ltd. Class H

(1501)

Select Model
Select Model
Select Model
Neutral 61 (OpenAI - Gpt-5.6Sol)
Rating:61Neutral
Price Target:
HK$36.00
â–²(22.87% Upside)
Action:Reiterated
Date:08/06/26
The score is driven primarily by solid underlying operating performance and improved 2025 cash generation, but is held back by the sharp increase in leverage and a weakening technical backdrop (trading below major moving averages with soft momentum). Valuation is moderate with a low dividend yield, offering only limited offset.
Positive Factors
Revenue Growth
Steady revenue expansion, including 12.7% annual growth in 2025, indicates continued demand for the company’s medical devices and consumables. Sustained top-line growth can support operating scale, strengthen customer reach, and provide a durable base for future earnings.
Negative Factors
Higher Leverage
The sharp increase in debt materially reduces financial flexibility and makes the company more sensitive to earnings volatility. Higher leverage can require greater cash allocation to financing obligations, potentially limiting investment capacity and increasing balance-sheet risk over the coming quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Steady revenue expansion, including 12.7% annual growth in 2025, indicates continued demand for the company’s medical devices and consumables. Sustained top-line growth can support operating scale, strengthen customer reach, and provide a durable base for future earnings.
Read all positive factors

Shanghai Kindly Medical Instruments Co., Ltd. Class H (1501) vs. iShares MSCI Hong Kong ETF (EWH)

Shanghai Kindly Medical Instruments Co., Ltd. Class H Business Overview & Revenue Model

Company Description
Shanghai Kindly Medical Instruments Co., Ltd., founded in 2006 and based in Shanghai, China, focuses on the research, development, production, and international sales of cardiovascular interventional medical devices. The company's products reach c...
How the Company Makes Money
The company primarily makes money by selling medical devices and related disposable/consumable products to healthcare providers (e.g., hospitals and clinics), generating revenue on a per-unit basis through product shipment/recognized sales. Revenu...

Shanghai Kindly Medical Instruments Co., Ltd. Class H Financial Statement Overview

Summary
Solid revenue growth and healthy profitability (2025 net margin ~20.5%, EBIT margin ~20.7%) are tempered by multi-year margin compression, a sharp 2025 increase in leverage (debt-to-equity ~0.36 vs ~0.14 in 2024), and historically volatile free cash flow despite a strong 2025 rebound.
Income Statement
74
Positive
Balance Sheet
67
Positive
Cash Flow
61
Positive
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue1.19B1.07B851.95M752.84M585.88M464.68M
Gross Profit725.48M636.79M537.66M438.07M332.49M275.75M
EBITDA378.17M353.06M255.43M225.88M159.99M168.81M
Net Income229.06M218.79M191.91M156.46M131.71M142.96M
Balance Sheet
Total Assets3.87B3.13B2.26B2.03B1.83B1.62B
Cash, Cash Equivalents and Short-Term Investments1.32B630.81M554.51M434.40M528.27M640.55M
Total Debt716.25M716.26M243.69M94.78M48.83M13.40M
Total Liabilities1.03B1.04B473.39M351.25M273.23M183.63M
Stockholders Equity2.76B2.00B1.77B1.65B1.51B1.40B
Cash Flow
Free Cash Flow212.14M278.17M59.80M-53.05M-62.75M-205.07M
Operating Cash Flow223.60M340.98M225.54M178.15M180.46M72.76M
Investing Cash Flow-212.45M-491.99M-187.31M-283.81M-316.18M-268.08M
Financing Cash Flow141.20M263.40M56.97M8.06M9.72M-31.07M

Shanghai Kindly Medical Instruments Co., Ltd. Class H Technical Analysis

Technical Analysis Sentiment
Negative
Last Price29.30
Price Trends
50DMA
33.01
Negative
100DMA
33.88
Negative
200DMA
32.42
Positive
Market Momentum
MACD
0.33
Positive
RSI
44.89
Neutral
STOCH
36.13
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1501, the sentiment is Negative. The current price of 29.3 is below the 20-day moving average (MA) of 33.97, below the 50-day MA of 33.01, and below the 200-day MA of 32.42, indicating a neutral trend. The MACD of 0.33 indicates Positive momentum. The RSI at 44.89 is Neutral, neither overbought nor oversold. The STOCH value of 36.13 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1501.

Shanghai Kindly Medical Instruments Co., Ltd. Class H Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
82
Outperform
HK$7.22B10.4920.11%3.79%12.50%44.44%
78
Outperform
HK$3.17B9.1110.50%5.33%16.25%7.80%
69
Neutral
HK$16.27B69.705.84%10.97%――
67
Neutral
HK$1.38B29.311.10%3.18%-1.64%-68.67%
61
Neutral
HK$6.97B24.339.64%0.77%34.94%12.99%
60
Neutral
HK$14.70B9.225.64%5.34%7.47%-26.89%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:1501
Shanghai Kindly Medical Instruments Co., Ltd. Class H
33.56
0.96
2.94%
HK:1066
Shandong Weigao Group Medical Polymer Co
3.24
-2.24
-40.88%
HK:1358
PW Medtech Group Ltd.
0.98
-0.47
-32.32%
HK:3600
Modern Dental Group Limited
7.65
2.38
45.18%
HK:6699
Angelalign Technology Inc.
96.15
29.84
44.99%
HK:6929
OrbusNeich Medical Group Holdings Limited
3.83
-0.45
-10.51%

Shanghai Kindly Medical Instruments Co., Ltd. Class H Corporate Events

Shanghai INT Medical Reshapes Board as It Prepares Mainland A-Share Listing
Aug 24, 2026
Shanghai INT Medical Instruments announced several board changes as it prepares for a mainland A-share listing, including the resignation of non-executive director Wang Ruiqin due to personal work adjustments. The company also disclosed that long-...
Shanghai INT Medical Instruments Sets Out Board and Committee Structure
Aug 24, 2026
Shanghai INT Medical Instruments Co., Ltd. has detailed the composition of its board of directors, which includes two executive directors, four non-executive directors, an employee representative director and three independent non-executive direct...
Shanghai INT Medical Instruments Boosts Revenue and Margins on Interventional Device Growth
Aug 24, 2026
Shanghai INT Medical Instruments reported robust growth for the six months ended 30 June 2026, with revenue rising 29.28% to RMB596.06 million, driven mainly by stronger sales of interventional medical devices. Revenue from these core products cli...
Shanghai Kindly Medical Sets Board Meeting to Approve Interim Results and Consider Dividend
Aug 12, 2026
Shanghai Kindly Medical Instruments Co., Ltd., a PRC-incorporated joint stock company listed in Hong Kong, operates in the medical instruments industry, supplying a range of healthcare-related devices through its subsidiaries. Its board comprises ...
Shanghai INT Medical Sets Extraordinary General Meeting and Closes Register of Members
Aug 10, 2026
Shanghai INT Medical Instruments Co., Ltd. has scheduled its first extraordinary general meeting of 2026 for 24 September, and will temporarily close its register of members from 25 August to 24 September to determine shareholder eligibility. Shar...
Shanghai INT Medical Expands Stake in Target Firm via US$55 Million Indirect Acquisition
Jul 23, 2026
Shanghai INT Medical Instruments has agreed, via a wholly owned subsidiary, to acquire 100% of the partnership interests in Shanghai Maoyi for US$55.1 million, which indirectly holds 579,866 series B preferred shares in a target company, equal to ...
Shanghai INT Medical Grants Performance-Linked H-Share Awards to Executive Director
Jun 29, 2026
Shanghai INT Medical Instruments has granted H-share awards under its existing H Share Award and Trust Scheme, which uses company funds for on-market purchases rather than issuing new shares. The awards, which form part of its long-term incentive ...
Shanghai INT Details Valuation and Compliance for Pulin Medical Stake Acquisition
Jun 25, 2026
Shanghai INT Medical Instruments Co., Ltd. has provided further details on its planned acquisition of a 35% equity stake in its non-wholly owned subsidiary, Shanghai Pulin Medical Instruments Co., Ltd., reinforcing its strategic focus on consolida...
Shanghai INT Medical Instruments Raises Stake in Target Company via Second Discloseable Acquisition
Jun 25, 2026
Shanghai INT Medical Instruments has agreed to further increase its stake in a target healthcare company by acquiring an additional 0.79% of its share capital, comprising 119,545 Series B preferred shares, for US$10 million. This follows its earli...
Shanghai INT Medical Instruments Starts Pre-Listing Tutoring for Potential A-Share Issue
Jun 12, 2026
Shanghai INT Medical Instruments Co., Ltd., a PRC-based medical device company listed in Hong Kong, plans to further expand its capital markets footprint by pursuing a potential A-share issuance on a stock exchange in mainland China. The move unde...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 06, 2026